甲状腺疾病与辅助生殖技术体外结局:不幸的组合?
本研究为单中心横断面研究,纳入279名女性、297个周期和1168个胚胎,探讨甲状腺过氧化物酶抗体/甲状腺自身免疫或甲状腺功能(血清促甲状腺激素)/亚临床甲状腺功能减退是否与获卵数、受精率和胚胎质量改变相关。结果显示,无甲状腺自身免疫女性中27%促甲状腺激素>2.5 mIU/L,甲状腺自身免疫患病率8%,6%女性促甲状腺激素>4.2 mIU/L;获卵数、受精率和胚胎质量在组间相当。回归分析中,年龄≥30岁和接受高卵巢刺激剂量(>2300 IU/周期)的女性正常获卵数率较低。结论不提示甲状腺抗体/自身免疫和(功能异常)对辅助生殖技术体外结局有影响。
要点
- 无甲状腺自身免疫女性中27%促甲状腺激素>2.5 mIU/L,甲状腺自身免疫患病率8%,6%女性促甲状腺激素>4.2 mIU/L。
- 获卵数、受精率和胚胎质量在甲状腺功能组间及甲状腺自身免疫有无组间相当。
- 年龄≥30岁和高卵巢刺激剂量(>2300 IU/周期)与正常获卵数率较低相关。
核心结论
- 结果不提示甲状腺抗体/自身免疫和(功能异常)对辅助生殖技术体外结局有影响。
研究设计与样本
- 单中心横断面研究,纳入279名女性,共297个周期和1168个胚胎。
主要发现
- 无甲状腺自身免疫女性中27%促甲状腺激素>2.5 mIU/L,甲状腺自身免疫患病率8%,总体6%女性促甲状腺激素>4.2 mIU/L。
- 获卵数、受精率和胚胎质量在研究组间相当。
- 回归分析中,年龄≥30岁女性正常获卵数率较低(OR 0.18 [95%CI 0.04-0.72];p=0.016)。
- 回归分析中,接受高卵巢刺激剂量(>2300 IU/周期)女性正常获卵数率较低(OR 0.17 [95%CI 0.06-0.48];p<0.001)。
关键数值与推荐
- 甲状腺功能分组依据促甲状腺激素≤2.5和>2.5 mIU/L(无甲状腺自身免疫女性)。
- 甲状腺自身免疫依据甲状腺过氧化物酶抗体存在与否确定。
- 胚胎质量按国际标准评估,分为优/良和差。
- 正常获卵数定义为>6或8,高受精率定义为>60%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The impact of thyroid disorders on in vitro outcomes of assisted reproductive technology (ART) remains controversial. Therefore, the aim of our study was to investigate whether thyroid peroxidase antibodies (TPO-Abs)/thyroid autoimmunity (TAI) or thyroid function (serum thyrotropin [TSH])/subclinical hypothyroidism are associated with an altered number of oocyte retrieval (NOR), fertilization rate (FR), and embryo quality (EQ). Methods: Cross-sectional study in 279 women in a single center, comprising 297 cycles and 1168 embryos. In vitro data (NOR, FR, and EQ) were documented in two groups; one according to thyroid function in women without TAI (TSH ≤2.5 and >2.5 mIU/L) and one according to the presence/absence of TAI (determined by TPO-Abs). EQ was evaluated according to international criteria and classified as excellent/good and poor. Women treated with levothyroxine (LT4) were excluded. Furthermore, the impact of thyroid parameters on outcomes, normal NOR (>6 or 8) and high FR (>60%), was verified in a multivariable logistic regression model. Results: In women without TAI, 27% had TSH levels >2.5 mIU/L, the prevalence of TAI was 8%, and overall, 6% of women had TSH levels >4.2 mIU/L. NOR, FR, and EQ were comparable between study groups. In the regression analysis, women aged ≥30 years and receiving a high ovarian stimulation dosage (>2300 IU/cycle) had lower rates of normal NOR (odds ratio [OR] 0.18 [95% confidence interval, CI 0.04-0.72]; p = 0.016 and OR 0.17 [CI 0.06-0.48]; p < 0.001, respectively). Conclusions: Our results do not suggest an impact of thyroid antibodies/autoimmunity and (dys)function on ART in vitro outcomes.
引用
- Poppe K, Autin C, Veltri F, et al. Thyroid Disorders and In Vitro Outcomes of Assisted Reproductive Technology: An Unfortunate Combination? Thyroid. 2020. PMID: 31950889. doi:10.1089/thy.2019.0567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。